Cancer name Ovarian Cancer
Cancer Type OV
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment SC144
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature gp130
Official Symbol IL6ST
Mode of action GLYC_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description After 6-hour continuous SC144 treatmentin OVCAR-8 and Caov-3 cells, the upper bands of total gp130 shifted to the lower band , indicating that SC144 treatment induced gp130 deglycosylation following the stimulation of gp130 phosphorylation.
PMID 23536726
Title Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer